These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682 [TBL] [Abstract][Full Text] [Related]
12. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269 [TBL] [Abstract][Full Text] [Related]
13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980 [TBL] [Abstract][Full Text] [Related]
14. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study. Kwak JH; Jun DW; Lee SM; Cho YK; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC Clin Nutr; 2018 Oct; 37(5):1550-1557. PubMed ID: 28918170 [TBL] [Abstract][Full Text] [Related]
15. The HAALT Non-invasive Scoring System for NAFLD in Obesity. Sheth H; Bagasrawala S; Shah M; Ansari R; Olithselvan A; Lakdawala M Obes Surg; 2019 Aug; 29(8):2562-2570. PubMed ID: 31016455 [TBL] [Abstract][Full Text] [Related]
16. Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity. Ooi GJ; Burton PR; Earnest A; Laurie C; Kemp WW; Nottle PD; McLean CA; Roberts SK; Brown WA Obes Surg; 2018 Feb; 28(2):427-436. PubMed ID: 28776153 [TBL] [Abstract][Full Text] [Related]
17. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687 [TBL] [Abstract][Full Text] [Related]
18. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Mann JP; Pietzner M; Wittemans LB; Rolfe EL; Kerrison ND; Imamura F; Forouhi NG; Fauman E; Allison ME; Griffin JL; Koulman A; Wareham NJ; Langenberg C Hum Mol Genet; 2020 Dec; 29(20):3451-3463. PubMed ID: 32720691 [TBL] [Abstract][Full Text] [Related]
20. The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease. Mosca A; De Cosmi V; Parazzini F; Raponi M; Alisi A; Agostoni C; Nobili V J Pediatr; 2019 Aug; 211():72-77.e4. PubMed ID: 31128886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]